Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 1
2011 2
2013 1
2014 2
2015 2
2016 1
2017 2
2018 1
2019 2
2020 4
2021 4
2022 2
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of kaposiform hemangioendothelioma and tufted angioma.
Liu XH, Li JY, Qu XH, Yan WL, Zhang L, Yang C, Zheng JW. Liu XH, et al. Int J Cancer. 2016 Oct 1;139(7):1658-66. doi: 10.1002/ijc.30216. Epub 2016 Jun 28. Int J Cancer. 2016. PMID: 27252149 Free article. Review.
This meta-analysis was to evaluate the efficacy of current treatment modalities for kaposiform hemangioendothelioma and tufted angioma. A systematic review was performed using PubMed (Medline), Web of Science and Embase for clinical studies. ...Thus, vincristine was …
This meta-analysis was to evaluate the efficacy of current treatment modalities for kaposiform hemangioendothelioma and tufted …
Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options.
Adams DM, Ricci KW. Adams DM, et al. Hematol Oncol Clin North Am. 2019 Jun;33(3):455-470. doi: 10.1016/j.hoc.2019.01.011. Hematol Oncol Clin North Am. 2019. PMID: 31030813 Review.
An increasing number of pediatric hematologists/oncologists are caring for individuals with vascular anomalies as these patients require chronic care and have high medical acuity needs. The advent of new medical therapy options, along with ongoing and upcoming clini …
An increasing number of pediatric hematologists/oncologists are caring for individuals with vascular anomalies as these patients require chr …
Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study.
Borst AJ, Eng W, Griffin M, Ricci KW, Engel E, Adams DM, Dayneka J, Cohen-Cutler SJ, Andreoli SM, Wu MD, Wheeler AP, Heym KM, Crary SE, Nakano TA, Schulte RR, Setty BA, McLean TW, Pahl KS, Intzes S, Pateva I, Teitelbaum M, Zong Z, Li Y, Jeng MR. Borst AJ, et al. Pediatr Blood Cancer. 2024 Mar;71(3):e30779. doi: 10.1002/pbc.30779. Epub 2023 Dec 10. Pediatr Blood Cancer. 2024. PMID: 38073018
BACKGROUND AND OBJECTIVES: Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children historically associated with significant morbidity and mortality. This study was conducted to determine first-line therapy in the abs …
BACKGROUND AND OBJECTIVES: Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children …
Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options.
Schmid I, Klenk AK, Sparber-Sauer M, Koscielniak E, Maxwell R, Häberle B. Schmid I, et al. World J Pediatr. 2018 Aug;14(4):322-329. doi: 10.1007/s12519-018-0171-5. Epub 2018 Jul 27. World J Pediatr. 2018. PMID: 30054848 Review.
BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor affecting infants and young children. ...If inoperable, response regarding KMP/regression of tumor size was seen in 29/28% with steroid-, 47/39% with vincristine-, 44/43% with interferon alph …
BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor affecting infants and young children. ...If inopera …
Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges.
Zhou J, Li Y, Qiu T, Gong X, Yang K, Zhang X, Zhang Z, Lan Y, Hu F, Peng Q, Zhang Y, Kong F, Chen S, Ji Y. Zhou J, et al. Int J Cancer. 2023 Aug 1;153(3):600-608. doi: 10.1002/ijc.34509. Epub 2023 Mar 22. Int J Cancer. 2023. PMID: 36916140
Treatment with sirolimus, an inhibitor of the mammalian target of rapamycin pathway, has improved the prognosis of patients with kaposiform hemangioendothelioma (KHE). However, the efficacy, durability and tolerability of long-term sirolimus treatment in patients wi …
Treatment with sirolimus, an inhibitor of the mammalian target of rapamycin pathway, has improved the prognosis of patients with kaposifo …
Sirolimus for the treatment of kaposiform hemangioendothelioma: In a trough level-dependent way.
Shan Y, Tian R, Gao H, Zhang L, Li J, Xie C, Liang Y, Chen Y, Wang J, Xu M, Gu S. Shan Y, et al. J Dermatol. 2021 Aug;48(8):1201-1209. doi: 10.1111/1346-8138.15905. Epub 2021 May 1. J Dermatol. 2021. PMID: 33932303
With the accumulation of clinical practice, sirolimus is now widely viewed as an effective agent in kaposiform hemangioendothelioma (KHE) treatment using a dose based on experience. ...
With the accumulation of clinical practice, sirolimus is now widely viewed as an effective agent in kaposiform hemangioendotheliom …
The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review.
Maza-Morales M, Valdés-Loperena S, Durán-McKinster LC, García-Romero MT. Maza-Morales M, et al. Pediatr Dermatol. 2023 May-Jun;40(3):440-445. doi: 10.1111/pde.15262. Epub 2023 Jan 30. Pediatr Dermatol. 2023. PMID: 36716766
BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a locally aggressive and potentially lethal vascular tumor of infancy. ...According to these findings, we suggest revised consensus treatment guidelines for KHE with mTOR inhibitors potentially considered first-li …
BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a locally aggressive and potentially lethal vascular tumor of infancy. .. …
Management of hemangiomas and other vascular tumors.
Greene AK. Greene AK. Clin Plast Surg. 2011 Jan;38(1):45-63. doi: 10.1016/j.cps.2010.08.001. Clin Plast Surg. 2011. PMID: 21095471 Review.
The 4 most common types are infantile hemangioma (IH), congenital hemangioma (CH), kaposiform hemangioendothelioma (KHE), and pyogenic granuloma (PG). ...
The 4 most common types are infantile hemangioma (IH), congenital hemangioma (CH), kaposiform hemangioendothelioma (KHE), and …
Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, Lu G, Liu X, Xia C, Wang Q, Li Y, Wang C, Yang K, Yang G, Tang X, Xu T, Wu H. Ji Y, et al. Int J Cancer. 2017 Aug 15;141(4):848-855. doi: 10.1002/ijc.30775. Epub 2017 May 26. Int J Cancer. 2017. PMID: 28486787 Free article.
Kaposiform hemangioendothelioma (KHE) is an aggressive disease with high morbidity and mortality. ...Sirolimus was effective and safe for the treatment of progressive KHE. Sirolimus may be considered as a first-line therapy or as part of a multidisciplinary a …
Kaposiform hemangioendothelioma (KHE) is an aggressive disease with high morbidity and mortality. ...Sirolimus was effective a …
Differential diagnosis of lower extremity enlargement in pediatric patients referred with a diagnosis of lymphedema.
Schook CC, Mulliken JB, Fishman SJ, Alomari AI, Grant FD, Greene AK. Schook CC, et al. Plast Reconstr Surg. 2011 Apr;127(4):1571-1581. doi: 10.1097/PRS.0b013e31820a64f3. Plast Reconstr Surg. 2011. PMID: 21187804 Review.
Forty-six children (27.1 percent) had another disorder: microcystic/macrocystic lymphatic malformation (19.6 percent), noneponymous combined vascular malformation (13.0 percent), capillary malformation (10.9 percent), Klippel-Trenaunay syndrome (10.9 percent), hemihypertrophy (8. …
Forty-six children (27.1 percent) had another disorder: microcystic/macrocystic lymphatic malformation (19.6 percent), noneponymous combined …
27 results